RT Journal Article
SR Electronic
T1 Nationwide, large-scale implementation of an online system for remote entry of patient-reported outcomes in rheumatology: characteristics of users and non-users and time to first entry
JF RMD Open
JO RMD Open
FD EULAR
SP e002549
DO 10.1136/rmdopen-2022-002549
VO 8
IS 2
A1 Glintborg, Bente
A1 Jensen, Dorte Vendelbo
A1 Terslev, Lene
A1 Hendricks, Oliver
A1 Østergaard, Mikkel
A1 Horskjær Rasmussen, Simon
A1 Jensen, Mogens Pfeiffer
A1 Adelsten, Thomas
A1 Colic, Ada
A1 Danebod, Kamilla
A1 Kildemand, Malene
A1 Loft, Anne Gitte
A1 Munk, Heidi Lausten
A1 Pedersen, Jens Kristian
A1 Østgård, René Drage
A1 Møller Sørensen, Christian
A1 Krogh, Niels Steen
A1 Agerbo, Jette
A1 Ziegler, Connie
A1 Hetland, Merete Lund
YR 2022
UL http://rmdopen.bmj.com/content/8/2/e002549.abstract
AB Aims In May 2020, a nationwide, web-based system for remote entry of patient-reported outcomes (PROs) in inflammatory rheumatic diseases was launched and implemented in routine care (DANBIO-from-home). After 1.5 years of use, we explored clinical characteristics of patients who did versus did not use the system, and the time to first entry of PROs.Methods All patients followed in DANBIO were informed about DANBIO-from-home by electronic invitations or when attending their clinic. Characteristics of patients who did/did not use DANBIO-from-home in the period after implementation were explored by multivariable logistic regression analyses including demographic and clinical variables (gender, age group, diagnosis, disease duration, use of biological disease-modifying agent (bDMARD), Health Assessment Questionnaire (HAQ), Patient Acceptable Symptom Scale (PASS)). Time from launch to first entry was presented as cumulative incidence curves by age group (<40/40–60/61–80/>80 years).Results Of 33 776 patients, 68% entered PROs using DANBIO-from-home at least once. Median (IQR) time to first entry was 27 (11–152) days. Factors associated with data entry in multivariate analyses (OR (95% CI)) were: female gender (1.19 (1.12 to 1.27)), bDMARD treatment (1.41 (1.33 to 1.50)), age 40–60 years (1.79 (1.63 to 1.97)), 61–80 years (1.87 (1.70 to 2.07), or age >80 years (0.57 (0.50 to 0.65)) (reference: age <40 years), lower HAQ (0.68 (0.65 to 0.71)) and PASS ‘no’ (1.09 (1.02 to 1.17). Diagnosis was not associated. Time to first entry of PROs was longest in patients <40 years of age (119 (24–184) days) and shortest in the 61–80 years age group (25 (8–139) days).Conclusion A nationwide online platform for PRO in rheumatology achieved widespread use. Higher age, male gender, conventional treatment and disability were associated with no use.All data relevant to the study are included in the article or uploaded as supplemental information. Data are available upon reasonable request.